Clinical Trial

A Study of AKR-001 in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Study Status:

Contact Information:

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose

This is a Phase 2a, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of AKR-001 in subjects with NASH. The purpose of this research study is to assess how well the different doses of AKR-001 work to reduce the amount of fat in the liver.

Information

Principal Investigator Rashmee Patil, MD
Co-PI
Sponsor Akero Therapeutics, Inc
Type of Trial Interventional